Epitomics launches 23 novel cancer-related antibodies

NewsGuard 100/100 Score
Jul 27 2011

Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal (RabMAb®) technology, today announced the Company has now launched 23 novel cancer-related antibodies that were developed through a partnership with the National Cancer Institute's Center for Cancer Research. The goal of this partnership is to develop novel, high quality reagents for cancer research and make them available to the scientific community.

"We are very excited to see the progress we have made in developing several key antibodies with NCI investigators and look forward to continuing working with them to develop high quality rabbit monoclonal antibodies," said Dr. Guo-Liang Yu, CEO, Epitomics, Inc.

SOURCE Epitomics, Inc.

Posted in: Medical Science News | Medical Condition News

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Breast cancer survivors at higher risk of developing second cancers
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases
MONET: New AI tool enhances medical imaging with deep learning and text analysis
Study links air pollution to increased colorectal cancer risk through DNA changes
New sustainable diagnostic approach offers precision cancer testing with minimal environmental impact
Researchers receive NIH grant to help develop gene therapy for HIV
Study unveils novel bladder cancer diagnostic model based on key mitochondrial genes
Aspirin's immune-boosting effects in colorectal cancer revealed

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer